跳至主要内容

Routes of Drug Administration Platform



Drug administration route is often classified by the location at which the drug is administered, such as oral or intravenous. The choice of routes in which the medication is given depends not only on convenience and compliance but also on the drug's pharmacokinetics and pharmacodynamic profile. Therefore it is crucial to understand the characteristics of the various routes and associated techniques as the first step before PK/PD, efficacy/pharmacology and toxicity study.

Intravenous Injection (i.v.)
  • Intravenous injection directly delivers the drugs to the systemic circulation. It is utilized when a rapid drug effect is desired, a precise serum drug level is needed, or when drugs are unstable or poorly absorbed in the gastrointestinal tract. It is also the route used in patients with altered mental status or severe nausea or vomiting, unable to tolerate oral medications.
    Advantages:
    Rapid onset of actionPredictable way of action and almost complete bioavailabilityThe problems of oral drug administration can be eliminated by avoiding the gastrointestinal tractThe best way of administration in very ill and comatose patients who cannot ingest anything orally
  • Medicilon Case: siRNA monkey PK/PD study
    CompoundMonkey MatrixAnimal NumberBA Assay
    siRNA
    IV infusion
    Plasma
    Muscle biopsy
    Liver biopsy
    N=2Cytokine study
    Complement study
    Lipid study
    Cir-luc mRNA
    IHC slide
    hELISA study
    MSTN Protein
    Plasma
    Muscle biopsy
    N=2hELISA study
    NHP mRNA
    NHP MSTN Protein
    IHC slide
    Cytokine study
    Complement study
  • Medicilon Case: Prophylactic cancer vaccines
    Medicilon Case: Prophylactic cancer vaccines.webp
  • Medicilon Case: Cancer vaccines
    Medicilon Case: Cancer vaccines.webp
Intratumoral Injection (i.t.)
  • Intratumoral immunotherapy is a strategy that offers a unique therapeutic and exploratory setting to better understand the immune contexture across tumor lesions of patients with metastatic cancer. Intratumoral immunotherapy turns cold tumors into hot and boosts the response rates to cancer immunotherapies while decreasing their systemic exposure and toxicities. Intratumoral immunotherapy improves the immunity against tumors and changes the combination therapy currently pursued for metastatic and local cancers to extend their survival.
    Intratumoral Injection VS Intravenous Management
    Nowadays, the primary methods of administration are systemic intravenous injection and direct intratumoral injection. Direct intratumoral injection could allow relatively small doses of spores to be used, ensuring that a larger effective dose reaches the target tumor and is distributed around the tip of the needle. Systemic injection requires large doses of injected spores; however, the proportion of spores delivered to the tumor is small with lower effective dose.
    Intratumoral Injection VS Intravenous Management.webp

    Comparison of intratumoral injection and intravenous management[1]

  • Medicilon Case: Comparing different drug delivery methods of mRNA
    MDA-MB-231 Xenograft Model in Female Nude Mice Tumor Volume (mm) (MeantSEM).webp
    MEDICILON Animals: Female BALB/c Nude mice
    Cells: MDA-MB-231, 5x106/mouse
    Model Establishment: Right flank SC injection
    Treatment: IV injection; TIW (three times a week);
    Group3, 4: mRNA (LNP) group.
    MDA-MB-231 Xenograft Model in Female Nude Mice Tumor Volume (mm3) (Mean±SEM).webp
    Animals: Female BALB/c Nude mice
           Cells: MDA-MB-231, 5x106/mouse
           Model Establishment: Right flank SC injection
           Treatment: Intratumor injection; TIW (three times a week);
           Group 7, 8: mRNA (LNP) group.
Subcutaneous Injection (SC)
  • Subcutaneous injection route is used when the drug's molecular size is too large to be effectively absorbed in the intestinal tract or when better bioavailability or a faster absorption rate is needed than the oral route. It is easy to administer and requires minimal skills, so patients can often self-administer the medication. Subcutaneous administration route is widely used to administer different types of drugs given its high bioavailability and rapid onset of action. There are remarkable advantages of subcutaneous injection over the other injection types, in contrast to IV and IM administrations, SC is less painful, the risk of infection is lower in SC than in IV injection. If this occurs, the infection is generally limited to a local infection rather than a systemic infection. Furthermore, subcutaneous injection offer a broader range of alternative sites than IM injection for those patients requiring multiple doses.
                Medicilon Case: siRNA and metabolite in rodent plasma and liver
    Medicilon Case: siRNA and metabolite in rodent plasma and liver.webp
    Administration RouteDose LevelAnalyteAUClast_liverAUClast_PlasmaAUClast_liver/AUClast_Plasma
    mg/kghr*ng/ghr*ng/g
    SC30siRNA_AS32976645178931843
    SC300siRNA_AS94450628219970429
Intradermal (Intracutaneous) Injection
  • Intradermal injection is administered into the dermis just below the epidermis. Intradermal injection has the longest absorption time of all parenteral routes because there are fewer blood vessels and no muscle tissue. The most common anatomical sites used for intradermal injection are the inner surface of the forearm and the upper back below the scapula. Intradermal injection provides a local and very little systemic effect. Intradermal injection is commonly used for tuberculin skin testing but can also be used for allergy testing and local anesthetics because the reaction is easy to visualize, and the degree of reaction can be assessed.
    Layers of Skin.webp

    Layers of Skin

                Medicilon Case: mRNA in PBMC humanized mice
    Medicilon Case: mRNA in PBMC humanized mice.webp
Intrathecal Injection (IT)
  • Intrathecal injection is a potential drug delivery approach with directly into cerebrospinal fluid (CSF) that fills the thecal sac. This route of administration can achieve a high concentration of therapeutic agent within the central nervous system (CNS) while minimizing off-target exposure and associated toxicity. However, the distribution of molecules following IT administration when they are provided in free form remains to be optimized. Many hydrophilic agents clear rapidly as CSF turns over, many hydrophobic agents experience delivery that is restricted near to the injection site, and many macromolecules can experience relatively limited parenchymal penetration. The potential significance of IT drug delivery for the treatment of CNS disease is amplified by deepened understanding of dynamic exchange between CSF, interstitial fluid (ISF), and peripheral tissue sites.
    Medicilon Case: Monkey IT validation work flow by concentration
    Medicilon Case: mRNA in PBMC humanized mice.webp
    Group No.Test MaterialDose LevelRoute & RegimenDose RatePlasma & CSF Collection
    1MED-0026 mg/MonkeyIT on Day 1
    6 monkeys
    2 mL (Infusion, 3 min)
    Location: Lumbar
    Post-dose at 4 h and 8 h
  • Medicilon Case: Monkey IT validation results by concentration
    Medicilon Case: Monkey IT validation results by concentration.webp
    Group No.Test MaterialDose LevelRoute & RegimenDose RatePlasma & CSF Collection
    1MED-0026 mg/MonkeyIT on Day 1
    6 monkeys
    2 mL (Infusion, 3 min)
    Location: Lumbar
    Post-dose at 4 h and 8 h
Intra-cisterna Magna Injection (ICM)
  • Intracisterna magna injection has been developed for enhanced CNS drug delivery. Intracisterna magna injection is widely used to bypass the blood-brain barrier and has distinct advantages for direct delivery into the CNS. An alternative to CSF-mediated delivery routes is lumbar IT injection and ICV infusion. Lumbar puncture used to obtain CSF or for chemotherapy is a highly skilled procedure that requires practical experience and specific knowledge of the relevant anatomy. In addition, cranial puncture site infections and intracerebral hemorrhage after ICV infusion are inherent surgical risks. Therefore, ICM administration has a clear advantage, given that it is widely used in animal models. In addition, the ICM route has been used extensively, particularly in NHPs, because it offers the easiest entry into the ventricles of the brain and subarachnoid space around the brain and spinal cord, except for craniotomy.
    Localization of the cisterna magna (CM) in monkey brain.webp

    Localization of the cisterna magna (CM) in monkey brain[2]

  • Medicilon Case: Preliminary Test of a Single Dose of MK-8931 in Cynomolgus Monkeys
    Group No.Number of AnimalsTest SubstanceConc. (ng/mL)Dose Volume mL/animalRoute/Frequency
    11MK-89312401sub-occipital puncture into the cisterna magna (1 min±10 s), once
    Cerebrospinal Fluid (CSF) Analysis
    MK-8931 Pharmacokinetics Analysis
    The LC-MS/MS analytical method for analyzing MK-8931 concentrations in CSF will be developed by ligand binding analysis laboratory in testing facility. The analytical results will be confirmed using quality control samples for intra-assay variation. The accuracy of at least 66.7% samples and 50% quality control samples at each concentration level should be within 80%-120%.
    Aβ40/ Aβ42 Analysis
    The Aβ40/Aβ42 level in CSF will be tested by bioanalysis laboratory in testing facility by using an ELISA kit.
Multiple Administration Routes
  • Medicilon Case: Nucleic acid drug delivery efficiency:siRNA
    Medicilon Case: Nucleic acid drug delivery efficiency:siRNA.webp
  • References:
    [1] Xu Feng, et al. Novel insights into the role of Clostridium novyi-NT related combination bacteriolytic therapy in solid tumors. Oncol Lett. 2021 Feb;21(2):110. doi: 10.3892/ol.2020.12371.
    [2] Junghyung Park, et al. XperCT-guided Intra-cisterna Magna Injection of Streptozotocin for Establishing an Alzheimer's Disease Model Using the Cynomolgus Monkey ( Macaca fascicularis). Exp Neurobiol. 2022 Dec 31;31(6):409-418. doi: 10.5607/en22027.

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati